• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    New Breast Implant Surgery Guidelines to Enhance Patient Safety

    Rhythm Management Group Debuts RhythmSynergy Tech Platform

    FDA Approves Trial Completion for Virtual Incision's MIRA Platform

    Thermo Fisher Scientific, Matrix Clinical Trials Enhance Research Solutions

    Medtronic, DaVita to Create New Kidney Care Firm
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Trademark Plastics Inc.

    BMP Medical

    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Trademark Plastics Inc.

    BMP Medical

    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Features

    The New Role of Regulatory Affairs in Medical Device Manufacturing

    Today’s market realities have reshaped the role of regulatory affairs within the medical device development process. But are companies keeping pace?

    Related CONTENT
    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    • Accu-Tube Appoints Matthew Haddle as CEO
    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    • CE Mark Granted to Predictive Software for Kidney Allograft Survival
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Kellen Hills, Contributing Writer11.13.14
    Call it a new paradigm. Call it a sea change. Or, if you prefer, call it downright frustrating. Whatever label you give to today’s medical device environment, the current and future reality is that the regulatory elements of medical technology are now just as important as how it’s designed, manufactured and marketed.

    How times have changed. Most medical device veterans (those with 30 years or more experience in the industry), will remember a time when registering a device was a much simpler, straightforward process. Prior to 1976, if a medical device developer wanted to get a product to market, it could be done without any government oversight. 

    However, as biocompatibility issues and health scares rose, pressure mounted against the United States government to institute medical device-specific rules and regulations. On May 28, 1976, the Food, Drug, and Cosmetic Act (FDCA) was amended to include regulation for medical devices, and required all medical devices be systematized into one of three classes, with Class I devices being the lowest risk (e.g., elastic bandages), Class III devices posing the greatest risk (e.g., an artificial heart), and Class II devices falling somewhere in-between (e.g., infusion pumps).

    In addition, Section 510(k) of the FDCA required device manufacturers to notify the U.S. Food and Drug Administration (FDA) of their intent to market a medical device. Up until 2009, these 510(k) submissions were relatively uncomplicated—certainly when compared to today’s 510(k) requirement—which is why for more than two decades, very few medical device companies had a dedicated regulatory affairs (RA) group. And if they did, RA usually only had limited involvement with product development, marketing and manufacturing.

    In 2012, RA’s role changed almost overnight with the passing of the Food and Drug Administration Safety and Innovation Act and the Medical Device User Fee Amendments of 2012, commonly called MDUFA III (the third iteration of the FDA’s user fee program). These pieces of legislation completely altered the regulatory landscape for medical device manufacturers (both OEM and contractor/suppliers). In addition to affecting how the FDA scrutinizes medical device manufacturers, the new rules also transformed the relationship between the regulatory affairs team and every other department within a medical device organization.

    Going forward, the only efficient, cost-effective, and compliant way for U.S. medical device companies to get their products to market in the United States and abroad is to involve regulatory affairs in every aspect of a medical device’s life cycle—from concept through post-market surveillance. By cultivating a collaborative relationship between regulatory affairs and all other departments within the organization, medical device companies will be better able to protect themselves, their resources, their customers and ultimately the patients who benefit from the device.

    Taking a 30,000-foot perspective, here’s how RA can offer valuable support and insight at each stage of a medical device’s life cycle:

    Concept and Feasibility Stage
    Many medical device companies have “future growth” teams that meet consistently to look at what their existing product portfolio is and what it should look like in five or 10 years. Without regulatory affairs involvement in these meetings, time and resources are likely to be wasted.

    For example, the research and development (R&D) team would present a concept for a novel product that would be launched in two years and submitted for 510(k) clearance. If the manufacturing department acknowledges that it is able to build it and marketing confirms that it will be able to sell it, the team would decide to move forward with concepting, prototyping and testing. Previously, RA would only be involved when the team felt it was ready for 510(k) submission.

    Today, the determining factors for whether a device qualifies for 510(k) or pre-market approval (PMA) submission have gotten much more stringent and convoluted. If the device concept is indeed novel, it is unlikely to have a predicate (or may be significantly different from the most comparable device), which means that it wouldn’t qualify for 510(k) submission. Instead, the FDA would require the device be submitted as a PMA. To move the submission process forward, the company first would have to spend millions of dollars in clinical trials and years getting it through the PMA process. With this information, the future growth team is likely to abandon the project. Had RA been involved in the team’s conversations from the outset, all of that time and money could have been saved.

    Preclinical Stage
    The bench testing required by the FDA for 510(k) and PMA submissions often is determined by available predicates, standards organizations and known device issues. RA is a valuable resource for gathering this information and helping the product development team identify the testing methods that will be required by the FDA and determining the most efficient, effective, and compliant testing strategy.

    For example, with a 510(k) submission, the FDA wants the medical device company to do the following:

    • Test their device.
    – If testing standards exist with acceptance criteria this process is fairly straightforward.
    – However, if there are no standards or existing standards do not include acceptance criteria, the burden is on the manufacturer to:
             * Test another legally U.S. marketed device (predicate) using the exact same testing method; and
             * Compare the devices head to head in order to prove that the newer device is substantially equivalent
               (in effect, as safe andeffective) as the predicate.
    – In some cases, published biomechanical literature may be used for comparative purposes as well.

    • The best way for any medical device manufacturer to approach testing is to run any and all design differences through their regulatory affairs team so that RA can help ensure that:
    – A predicate exists that the FDA will accept;
    – There’s a solid risk management plan in place;
    – FDA guidance documents for testing are adhered to; and
    – All available standards and literature for testing are evaluated and applied where appropriate.

    Marketing Stage
    Marketing has the formidable job of turning engineering-speak into decipherable features and benefits that will help sell the medical device. Highlighting the unique and novel attributes of the device that differentiate it from the competition is an important part of that process. However, since the majority of devices in the United States are cleared through the “me too” 510(k) process, those attributes can’t be too different from currently marketed predicates without opening the company up to FDA scrutiny and warning letters.

    By planning ahead and coming up with potential claims and message points while the device is still in the early concept and prototyping stage, and then running those concepts by regulatory affairs, marketing increases the likelihood that its claims won’t raise red flags with the FDA (even though FDA does not, technically, review and approve claims). For example, if marketing decides on certain performance claims while still in the early stages of product development, RA can help guide the preclinical team on testing methods and strategies that will help substantiate those claims. In other cases, RA might determine that adding something as simple as a qualifier (e.g., “data on file” or device “may” or “is intended to”) to the marketing piece will be sufficient.

    From an RA perspective, it’s never about just staying, “No, you can’t make that claim.” It’s about working collaboratively with marketing to figure out what needs to be done in order to substantiate a claim so the company won’t find itself in legal or regulatory crosshairs.

    Manufacturing/Production Stage
    Until recently, a typical medical device manufacturing team worked (for the most part) independently of regulatory affairs. If manufacturing wanted to machine a part instead of forge it, or change to a different supplier, they may do so without perceiving the need to notify anyone in regulatory affairs. But in today’s tightly regulated medical device environment, that independent decision-making can have severe repercussions for a medical device company.

    Change control has become a major sticking point with the FDA and with international governments. Even the smallest, most seemingly insignificant change could actually shut down a company’s business in parts of the world. RA has the insights to help ensure that any medical device-related change will adhere to both U.S. and global regulatory requirements, which is why it’s vital for manufacturing and regulatory affairs to work collaboratively.

    The level of involvement, control, and notification that is required depends on the type of device, its classification, where and how it is marketed, and a host of other factors. For example, a U.S. medical device manufacturer selling a device in another country may need to notify that country’s regulatory agency if it wanted to move an operation to a new facility or supplier. In addition, because most regulatory agencies expect high-level change control detail, it’s possible that the authorities not only would require the company to notify them of such a change, but to halt imports of any products into the country until the appropriate documentation has been reviewed and approved. The RA team is equipped to help manufacturing navigate these complicated regulatory nuances so work can be completed with as little disruption or risk to the company as possible.

    Post-Market Stage
    Currently, U.S. regulations are not on par with European and other international regulations for post-market surveillance.  For the most common 510(k) devices, U.S. regulations do not require manufacturers to actively collect data on device performance.  Instead, they tend to rely on complaints from the field and report only the most serious adverse events, even though a lack of complaints does not mean the device is performing well. 

    In regions outside of the U.S., after a product gets to market and is in use, the expectation is that the medical device company will diligently, consistently and proactively follow up on their products and track:

    • Who is using the device;
    • How the device is performing months and even years after a procedure; and
    • How similar devices are performing.

    When a U.S. company tries to sell its product outside of the United States, the firm often finds itself unprepared and ill-equipped. This especially is true for companies with no experience dealing with international medical device regulations. Their assumption is that since it was cleared through the FDA, it should be a fairly straightforward process getting it to market in Europe or Asia. But without extensive post-market data, this couldn’t be further from the truth.

    This mindset with U.S. companies and within the FDA is gradually changing. In fact, once the present 510(k) issues are sorted out in the United States, it’s very likely that the FDA will start scrutinizing post-market surveillance as well. The FDA already has started putting the framework together for new post-market surveillance requirements, which means that medical device companies should expect to soon feel the pressure to gather better information about their device’s total product life cycle and to implement more robust risk management and change control procedures. 

    To Protect and Serve
    Regulatory professionals often are referred to as “police” in today’s global medical device marketplace, and much like local law enforcement, regulatory affairs’ job is to two-fold: Protect the medical device manufacturer from getting into trouble with the authorities regulating them; and serve the needs of all stakeholders by helping to ensure that the company gets safe, reliable products to market efficiently and cost-effectively—without any barriers to clearance.

    * * *
    To adequately do their job, RA must be included in the conversations that take place at each stage of the device’s life cycle. By involving RA in every key device-related meeting and decision; allowing them to review designs early; and collaborating with RA on test plans, reports, and timelines, medical device manufacturers will be better able to succeed with their innovations and with their business.

    For medical device companies that do not have an in-house regulatory affairs group, it’s essential to work with a company that has extensive RA expertise, direct communication with the FDA, and can provide accurate and prompt clarification on PMA and 510(k) submissions. 


    Kellen Hills is the senior regulatory consultant for Orchid Orthopedic Solutions. In addition to designing and manufacturing implants and instruments for the orthopedic, dental and cardiovascular markets, Orchid provides regulatory expertise, document preparation, and submission strategies to help medical device companies ensure regulatory compliance from concept to post-market surveillance.
    Related Searches
    • medical device company
    • Medical Devices
    • medical device companies
    • lifepak 1000 defibrillator
    Related Knowledge Center
    • Contract Manufacturing
    • Testing
    • R&D & Design
    Suggested For You
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board
    Stryker Buys Gauss Surgical Stryker Buys Gauss Surgical

    Related Content

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21


    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21


      Trending
      • 5 Ways Plastics Revolutionized The Healthcare Industry | Medical Product Outsourcing
      • Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status | Medical Product Outsourcing
      • FDA Clears Masimo's Neonatal RD SET Pulse Oximetry Sensors With Improved Accuracy Specifications | Medical Product Outsourcing
      • Medtronic, DaVita To Create New Kidney Care Firm | Medical Product Outsourcing
      • 7 Steps To Create Your Own Medical Device Marketing Plan | Medical Product Outsourcing
      Breaking News
      • New Breast Implant Surgery Guidelines to Enhance Patient Safety
      • Rhythm Management Group Debuts RhythmSynergy Tech Platform
      • FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      • Thermo Fisher Scientific, Matrix Clinical Trials Enhance Research Solutions
      • Medtronic, DaVita to Create New Kidney Care Firm
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      Sustainability, Economy are Focus of BCF’s Annual Conference
      Demand for Rhino Shield Increases
      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      iECURE Enters Agreement with Center for Breakthrough Medicines
      CPDC Enters Clinical Manufacturing Deal with CellBion
      Olon to Build New R&D Center in Italy
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      Zeller+Gmelin Honored as Berry Global’s 2021 Ink Supplier of the Year
      Paul N. Gardner USA Introduces New PosiTector GLS Gloss Meter
      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      UPM Raflatac accelerates label growth with acquisition
      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login